China Approves Satri-Cel, World’s First CAR T-Cell Therapy for Claudin 18.2-Positive Gastric Cancer

September 6, 2026

PubMed China

Overview

China’s National Medical Products Administration (NMPA) has approved satricabtagene autoleucel (satri-cel), a CAR T-cell therapy for Claudin 18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. This marks the world’s first CAR T-cell therapy approved for solid tumors. Phase II clinical trials demonstrated significant improvements in progression-free survival and overall survival for treated patients. This approval represents a landmark expansion of CAR T-cell therapy beyond hematological malignancies into solid tumors, significantly impacting future oncology treatment paradigms.

In Depth

Key Finding: First CAR T-Cell Therapy Approved for Solid Tumors

China’s National Medical Products Administration (NMPA) has approved satricabtagene autoleucel (satri-cel), a CAR T-cell therapy targeting Claudin 18.2-positive, HER2-negative advanced or metastatic gastric and gastroesophageal junction adenocarcinoma. This landmark approval marks the first time a CAR T-cell therapy, previously successful in hematological malignancies, has been sanctioned for solid tumors, which are notoriously challenging to treat.

Clinical Details: Improved Progression-Free and Overall Survival

The approval of satri-cel is based on the pivotal Phase II clinical trial results. This trial demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) for patients with Claudin 18.2-positive gastric cancer who had progressed on prior therapies. While specific response rates and median survival data remain undisclosed, the findings unequivocally support the efficacy of CAR T-cell therapy in solid tumors. The safety profile was deemed manageable, with severe cytokine release syndrome (CRS) and neurotoxicity events reported within the range observed for existing CAR T therapies.

Background and Industry Context: A New Dawn for Solid Tumor Treatment

CAR T-cell therapies have achieved remarkable success in treating hematological cancers by targeting antigens like CD19 and BCMA. However, solid tumors present formidable challenges due to their complex microenvironment, heterogeneous antigen expression, and issues with CAR T-cell infiltration and persistence. Claudin 18.2, expressed in approximately 30-50% of gastric cancer patients, represents a promising solid tumor target. Satri-cel has overcome some of these challenges by specifically recognizing and attacking this target. This approval is expected to intensify the development race for CAR T-cell therapies in solid tumors and accelerate the exploration of novel therapeutic strategies.

Future Outlook: Expanding Indications and Technological Innovation

This approval not only provides a new treatment option for gastric cancer patients but also suggests potential for label expansion to other Claudin 18.2-positive solid tumors, such as pancreatic cancer. Future research will likely focus on combination therapies, improved CAR T-cell designs, and the development of more robust cell manufacturing processes to further enhance efficacy in solid tumors. This success will significantly impact the global cell therapy industry and heralds the beginning of a paradigm shift in solid tumor oncology.

Source: https://pubmed.ncbi.nlm.nih.gov/42478469/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.